CLINICAL TRIALS PROFILE FOR EVENITY
✉ Email this page to a colleague
All Clinical Trials for EVENITY
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00907296 ↗ | Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing | Completed | UCB Pharma | Phase 2 | 2009-09-02 | The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone). |
NCT00907296 ↗ | Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing | Completed | Amgen | Phase 2 | 2009-09-02 | The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone). |
NCT01081678 ↗ | Study To Assess FRacTure Healing With SclerosTin Antibody - Hip | Completed | Amgen | Phase 2 | 2010-06-20 | This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation. |
NCT01631214 ↗ | Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis | Completed | Amgen | Phase 3 | 2012-05-04 | The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis. |
NCT02791516 ↗ | A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis | Completed | Amgen | Phase 3 | 2017-01-16 | The primary objective is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis. |
NCT03432533 ↗ | A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis | Completed | Amgen | Phase 3 | 2018-02-06 | To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen) |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EVENITY
Condition Name
Clinical Trial Locations for EVENITY
Trials by Country
Clinical Trial Progress for EVENITY
Clinical Trial Phase
Clinical Trial Sponsors for EVENITY
Sponsor Name